Scientists have shown that a drug combination slows cancer cell growth in a type of non small cell lung cancer when tested in the lab, offering potential for developing new treatments in the future. Cancer Research UK | British Journal of Cancer
The drug combination delivers a double whammy to the way the KRAS gene makes cancer cells grow. KRAS is estimated to be mutated in 15 to 25 per cent of people with non-small cell lung adenocarcinomas – a disease affecting around 10,400 people in England each year.
The study looked at whether blocking the functions of two proteins called MEK and m-TOR would stop or slow down the growth of non-small cell lung adenocarcinoma cells in the laboratory.
Full reference: Broutin, S. et al. Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. Br J Cancer 115: 549-552; doi:10.1038/bjc.2016.220